Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $790.02 million. The enterprise value is $569.40 million.
Important Dates
The last earnings date was Tuesday, April 28, 2026, after market close.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 61.67 million shares outstanding. The number of shares has increased by 1.31% in one year.
| Current Share Class | 61.67M |
| Shares Outstanding | 61.67M |
| Shares Change (YoY) | +1.31% |
| Shares Change (QoQ) | +3.13% |
| Owned by Insiders (%) | 14.44% |
| Owned by Institutions (%) | 42.70% |
| Float | 29.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.67 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.28 |
| Quick Ratio | 21.87 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.26% and return on invested capital (ROIC) is -21.75%.
| Return on Equity (ROE) | -31.26% |
| Return on Assets (ROA) | -20.93% |
| Return on Invested Capital (ROIC) | -21.75% |
| Return on Capital Employed (ROCE) | -35.58% |
| Weighted Average Cost of Capital (WACC) | 12.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +230.16% in the last 52 weeks. The beta is 1.58, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +230.16% |
| 50-Day Moving Average | 11.19 |
| 200-Day Moving Average | 8.24 |
| Relative Strength Index (RSI) | 59.99 |
| Average Volume (20 Days) | 352,317 |
Short Selling Information
The latest short interest is 2.24 million, so 3.63% of the outstanding shares have been sold short.
| Short Interest | 2.24M |
| Short Previous Month | 2.08M |
| Short % of Shares Out | 3.63% |
| Short % of Float | 7.66% |
| Short Ratio (days to cover) | 6.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | -59.13M |
| Operating Income | -78.36M |
| Pretax Income | -69.71M |
| Net Income | -69.71M |
| EBITDA | -77.74M |
| EBIT | -78.36M |
| Earnings Per Share (EPS) | -$1.20 |
Full Income StatementBalance Sheet
The company has $222.82 million in cash and $2.20 million in debt, giving a net cash position of $220.63 million or $3.58 per share.
| Cash & Cash Equivalents | 222.82M |
| Total Debt | 2.20M |
| Net Cash | 220.63M |
| Net Cash Per Share | $3.58 |
| Equity (Book Value) | 218.05M |
| Book Value Per Share | 3.49 |
| Working Capital | 216.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$54.00 million and capital expenditures -$121,000, giving a free cash flow of -$54.55 million.
| Operating Cash Flow | -54.00M |
| Capital Expenditures | -121,000 |
| Depreciation & Amortization | 622,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -54.55M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |